Proportion of participants with self‐rated clinically significant hair regrowth · women with FPHL
Minoxidil probably leads to higher the proportion of participants with self‐rated clinically… compared with placebo (moderate certainty).
1 finding from 1 review
Change in quality of life · women with FPHL
1 finding from 1 review
Adverse events · women with FPHL
Minoxidil showed no clear difference in adverse events compared with placebo (low certainty).
1 finding from 1 review
Proportion of participants with investigator‐rated clinically significant hair regrowth · women with FPHL
Minoxidil probably leads to higher proportion of participants with investigator‐rated clinically… compared with placebo (moderate certainty).
1 finding from 1 review
Change from baseline to study conclusion in total hair count · women with FPHL
1 finding from 1 review
Degree of hair shedding from baseline to the end of the study · women with FPHL
1 finding from 1 review
Cosmetic appearance of the hair or participant satisfaction · women with FPHL
1 finding from 1 review
Change in quality (or pattern) of hair regrowth (e.g. thickness) · women with FPHL
1 finding from 1 review
Short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of · adults with alopecia areata
It is very uncertain whether summary of findings table ‐ Topical hair growth stimulants (minoxidil) changes short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of compared with placebo (very low certainty).
1 finding from 1 review
Incidence of serious adverse events · adults with alopecia areata
1 finding from 1 review
Health‐related quality of life ‐ not reported · adults with alopecia areata
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Long‐term hair regrowth ≥ 75% (greater than 26 weeks of · adults with alopecia areata
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found